FENC - NASDAQ
Fennec Pharmaceuticals Inc.
$9.35
-6.3%Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
At a Glance
Live SnapshotFennec Pharmaceuticals Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Fennec Pharmaceuticals Inc. Income Statement
FENC • NASDAQ
| Fennec Pharmaceuticals Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
44.6M | 47.5M | 21.3M | 1.5M | 0.0 | 170K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
GROSS PROFIT | ||||||||||||||||||||
(3.8M) | (3.2M) | (1.3M) | (82.6K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
40.9M | 44.4M | 20M | 1.4M | 0.0 | 170K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
OPERATING INCOME | ||||||||||||||||||||
(47.2M) | (41.8M) | (32.8M) | (23.1M) | (17.1M) | (18.1M) | (13M) | (10.4M) | (7M) | (2.9M) | (1.9M) | (2.9M) | (1.9M) | (3.6M) | (3.4M) | (4.6M) | (2.8M) | (13.9M) | (14.2M) | (19.1M) | |
(46.9M) | (41.5M) | (32.7M) | (19.7M) | (12.1M) | (13M) | (7.4M) | (5.4M) | (5M) | (2.4M) | (1.6M) | (2.5M) | (1.3M) | (1.5M) | (1.9M) | (3.9M) | (1.2M) | (3.5M) | (3.3M) | (2.9M) | |
(250K) | (307K) | (56K) | (3.4M) | (4.9M) | (5.1M) | (5.6M) | (5M) | (1.9M) | (472K) | (256K) | (357K) | (597K) | (2.1M) | (1.5M) | (708K) | (2.1M) | (10.4M) | (10.9M) | (14M) | |
-6.3M | 2.6M | -12.8M | -21.7M | -17.1M | -17.9M | -13M | -10.4M | -7M | -2.9M | -1.9M | -2.9M | -1.9M | -3.6M | -3.4M | -4.6M | -3.2M | -13.9M | -14.2M | -19.1M | |
PRE-TAX INCOME | ||||||||||||||||||||
(2.1M) | (4.1M) | (3.4M) | (978K) | (126K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (2K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -3K | |
-1.3M | -2.5M | -3M | -783K | -72K | 91.6K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
(64K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -17K | (6K) | -8K | -14K | (0.0) | (0.0) | -3K | -5K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (2.2M) | |
-3.3M | -2.6M | -3.3M | -1.1M | -121.9K | -224K | 234K | 521K | -95K | 82K | 1.3M | 701K | 3.8M | -1.5M | 8.1M | -3.5M | 204K | 0.0 | 906K | -1.5M | |
-9.6M | -71K | -16M | -22.8M | -17.2M | -18.1M | -12.8M | -9.9M | -7M | -2.8M | -659K | -2.2M | 1.8M | -5.2M | 4.7M | -7.8M | -3M | -13.6M | -13.4M | -20.6M | |
NET INCOME | ||||||||||||||||||||
(106K) | (365K) | (0.0) | (0.0) | (0.0) | (0.0) | -315K | -348K | -47K | -8K | -3K | -2K | -2K | -25K | -43K | (7.8M) | (3M) | (13.6M) | (13.4M) | -1.5M | |
-9.7M | -436K | -16M | -22.8M | -17.2M | -18.1M | -12.5M | -9.9M | -7M | -2.8M | -659K | -2.2M | 1.8M | -5.2M | 4.7M | -7.8M | -3M | -13.6M | -13.4M | -19.1M |
SEC Filings
FENC - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 22, 2026 | May 21, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 18, 2026 | May 18, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 14, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 28, 2026 | April 27, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | June 10, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 22, 2026 | April 22, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 07, 2026 | April 07, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 27, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 24, 2026 | March 24, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 16, 2026 | March 16, 2026 | 2026 |
Related Guides
Continue your FENC research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.